Blind patients in end-stage inherited retinal degeneration: multimodal imaging of candidates for artificial retinal prosthesis.
Journal
Eye (London, England)
ISSN: 1476-5454
Titre abrégé: Eye (Lond)
Pays: England
ID NLM: 8703986
Informations de publication
Date de publication:
01 2021
01 2021
Historique:
received:
10
07
2020
accepted:
14
09
2020
revised:
11
09
2020
pubmed:
11
10
2020
medline:
22
6
2021
entrez:
10
10
2020
Statut:
ppublish
Résumé
To characterize the imaging features of blind patients with end-stage inherited retinal degeneration (IRD) and to assess possible morpho-functional correlations. In this observational cross-sectional study, we reviewed the clinical data and multimodal imaging of 40 eyes of 21 blind (light perception or less) institutional patients affected by end-stage IRD screened for Alpha AMS (Retina Implant AG, Reutlingen, Germany) retinal prosthesis eligibility. Analysis was carried out using spectral-domain optical coherence tomography (SD-OCT), fluorescein angiography and fundus autofluorescence. Among patients with IRD-related low vision, the extrapolated prevalence of the blind was roughly 10%, median age 60.4 years with a disease duration of 40.4 years, showing epiretinal membranes (80%), hyperreflective intraretinal nodules (90%) and the absence of the ellipsoid zone (77.5%) on SD-OCT examination. Cystoid macular oedema was present in 52.5% of eyes, the majority of which being of the microcystoid subtype (42.5%), while 37.5% of eyes also lacked outer and inner retinal layer segmentation. Disease duration was found to be predictive of disrupted retinal layers (P = 0.029) and microcystoid macular oedema (P = 0.035), which was also more frequent in eyes without light perception (P = 0.013). Eyes without vision due to end-stage IRD have a typical imaging pattern, predominantly characterized by epiretinal membranes, hyperreflective intraretinal nodules and the absence of the ellipsoid zone. Furthermore, microcystoid macular oedema and retinal layer disruption may be considered as signs of longstanding disease.
Identifiants
pubmed: 33037412
doi: 10.1038/s41433-020-01188-0
pii: 10.1038/s41433-020-01188-0
pmc: PMC7852521
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
289-298Références
Liew G, Michaelides M, Bunce C. A comparison of the causes of blindness certifications in England and Wales in working age adults (16-64 years), 1999-2000 with 2009-2010. BMJ Open. 2014;4:e004015.
doi: 10.1136/bmjopen-2013-004015
Ferrari S, Di Iorio E, Barbaro V, Ponzin D, Sorrentino FS, Parmeggiani F. Retinitis pigmentosa: genes and disease mechanisms. Curr Genom. 2011;12:238–49.
doi: 10.2174/138920211795860107
Iftikhar M, Usmani B, Sanyal A, Kherani S, Sodhi S, Bagheri S, et al. Progression of retinitis pigmentosa on multimodal imaging: the PREP-1 study. Clin Exp Ophthalmol. 2019;47:605–13.
pubmed: 30552737
Grover S, Fishman GA, Anderson RJ, Tozatti MSV, Heckenlively JR, Weleber RG, et al. Visual acuity impairment in patients with retinitis pigmentosa at age 45 years or older. Ophthalmology. 1999;106:1780–5.
doi: 10.1016/S0161-6420(99)90342-1
Grover S, Fishman GA, Alexander KR, Anderson RJ, Derlacki DJ. Visual acuity impairment in patients with retinitis pigmentosa. Ophthalmology. 1996;103:1593–600.
doi: 10.1016/S0161-6420(96)30458-2
Bainbridge JWB, Smith AJ, Barker SS, Robbie S, Henderson R, Balaggan K, et al. Effect of gene therapy on visual function in Leber’s congenital amaurosis. N Engl J Med. 2008;358:2231–9.
doi: 10.1056/NEJMoa0802268
MacLaren RE, Groppe M, Barnard AR, Cottriall CL, Tolmachova T, Seymour L, et al. Retinal gene therapy in patients with choroideremia: Initial findings from a phase 1/2 clinical trial. Lancet. 2014;383:1129–37.
doi: 10.1016/S0140-6736(13)62117-0
Bennett J, Wellman J, Marshall KA, McCague S, Ashtari M, DiStefano-Pappas J, et al. Safety and durability of effect of contralateral-eye administration of AAV2 gene therapy in patients with childhood-onset blindness caused by RPE65 mutations: a follow-on phase 1 trial. Lancet. 2016;388:661–72.
doi: 10.1016/S0140-6736(16)30371-3
Prado DA, Acosta-Acero M, Maldonado RS. Gene therapy beyond luxturna: a new horizon of the treatment for inherited retinal disease. Curr Opin Ophthalmol. 2020;31:147–54.
Schatz A, Röck T, Naycheva L, Willmann G, Wilhelm B, Peters T, et al. Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Investig Ophthalmol Vis Sci. 2011;52:4485–96.
doi: 10.1167/iovs.10-6932
Schatz A, Pach J, Gosheva M, Naycheva L, Willmann G, Wilhelm B, et al. Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled follow-up study over 1 year. Investig Ophthalmol Vis Sci. 2017;58:257–69.
doi: 10.1167/iovs.16-19906
Busskamp V, Picaud S, Sahel JA, Roska B. Optogenetic therapy for retinitis pigmentosa. Gene Ther. 2012;19:169–75.
doi: 10.1038/gt.2011.155
Singh MS, Charbel Issa P, Butler R, Martin C, Lipinski DM, Sekaran S, et al. Reversal of end-stage retinal degeneration and restoration of visual function by photoreceptor transplantation. Proc Natl Acad Sci USA. 2013;110:1101–6.
doi: 10.1073/pnas.1119416110
Scholl HPN, Moore AT, Koenekoop RK, Wen Y, Fishman GA, Van Den Born LI, et al. Safety and proof-of-concept study of oral QLT091001 in retinitis pigmentosa due to inherited deficiencies of retinal pigment epithelial 65 protein (RPE65) or lecithin: retinol acyltransferase (LRAT). PLoS ONE. 2015;10:e0143846.
Zrenner E, Bartz-Schmidt KU, Benav H, Besch D, Bruckmann A, Gabel VP, et al. Subretinal electronic chips allow blind patients to read letters and combine them to words. Proc R Soc B Biol Sci. 2011;278:1489–97.
doi: 10.1098/rspb.2010.1747
Humayun MS, Dorn JD, Da Cruz L, Dagnelie G, Sahel JA, Stanga PE, et al. Interim results from the international trial of second sight’s visual prosthesis. Ophthalmology. 2012;119:779–88.
doi: 10.1016/j.ophtha.2011.09.028
Ayton LN, Blamey PJ, Guymer RH, Luu CD, Nayagam DAX, Sinclair NC, et al. First-in-human trial of a novel suprachoroidal retinal prosthesis. PLoS ONE. 2014;9:e115239.
Stingl K, Bartz-Schmidt KU, Besch D, Chee CK, Cottriall CL, Gekeler F, et al. Subretinal visual implant alpha IMS-clinical trial interim report. Vis Res. 2015;111:149–60.
doi: 10.1016/j.visres.2015.03.001
Maya-Vetencourt JF, Ghezzi D, Antognazza MR, Colombo E, Mete M, Feyen P, et al. A fully organic retinal prosthesis restores vision in a rat model of degenerative blindness. Nat Mater. 2017;16:681–9.
doi: 10.1038/nmat4874
Stingl K, Schippert R, Bartz-Schmidt KU, Besch D, Cottriall CL, Edwards TL, et al. Interim results of a multicenter trial with the new electronic subretinal implant alpha AMS in 15 patients blind from inherited retinal degenerations. Front Neurosci. 2017;11:445.
doi: 10.3389/fnins.2017.00445
Edwards TL, Cottriall CL, Xue K, Simunovic MP, Ramsden JD, Zrenner E, et al. Assessment of the electronic retinal implant alpha AMS in restoring vision to blind patients with end-stage retinitis pigmentosa. Ophthalmology. 2018;125:432–43.
doi: 10.1016/j.ophtha.2017.09.019
Zrenner E. Fighting blindness with microelectronics. Sci Transl Med. 2013;5:210ps16.
doi: 10.1126/scitranslmed.3007399
Bach M. Freiburg visual acuity & contrast test (FrACT). 2002. https://michaelbach.de/fract/index.html .
Schulze-Bonsel K, Feltgen N, Burau H, Hansen L, Bach M. Visual acuities “hand motion” and “counting fingers” can be quantified with the Freiburg Visual Acuity Test. Investig Ophthalmol Vis Sci. 2006;47:1236–40.
doi: 10.1167/iovs.05-0981
Lieberman HR, Pentland AP. Microcomputer-based estimation of psychophysical thresholds: The Best PEST. Behav Res Methods Instrum. 1982;14:21–5.
doi: 10.3758/BF03202110
Treutwein B. Adaptive psychophysical procedures. Vis Res. 1995;35:2503–22.
doi: 10.1016/0042-6989(95)00016-X
Bach M. Anti-aliasing and dithering in the “Freiburg Visual Acuity Test.”. Spat Vis. 1997;11:85–9.
doi: 10.1163/156856897X00087
Campochiaro PA, Mir TA. The mechanism of cone cell death in Retinitis Pigmentosa. Prog Retin Eye Res. 2018;62:24–37.
doi: 10.1016/j.preteyeres.2017.08.004
Punzo C, Kornacker K, Cepko CL. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat Neurosci. 2009;12:44–52.
doi: 10.1038/nn.2234
Wang AL, Knight DK, Vu TTT, Mehta MC. Retinitis pigmentosa: review of current treatment. Int Ophthalmol Clin. 2019;59:263–80.
Triolo G, Pierro L, Parodi MB, De Benedetto U, Gagliardi M, Manitto MP, et al. Spectral domain optical coherence tomography findings in patients with retinitis pigmentosa. Ophthalmic Res. 2013;50:160–4.
doi: 10.1159/000351681
Nagasaka Y, Ito Y, Ueno S, Terasaki H. Number of hyperreflective foci in the outer retina correlates with inflammation and photoreceptor degeneration in retinitis pigmentosa. Ophthalmol Retin. 2018;2:726–34.
doi: 10.1016/j.oret.2017.07.020
Schuerch K, Marsiglia M, Lee W, Tsang SH, Sparrow JR. Multimodal imaging of disease-associated pigmentary changes in retinitis pigmentosa. Retina. 2016;36:S147–58.
doi: 10.1097/IAE.0000000000001256
Aizawa S, Mitamura Y, Baba T, Hagiwara A, Ogata K, Yamamoto S. Correlation between visual function and photoreceptor inner/outer segment junction in patients with retinitis pigmentosa. Eye. 2009;23:304–8.
doi: 10.1038/sj.eye.6703076
Kim YJ, Joe SG, Lee DH, Lee JY, Kim JG, Yoon YH. Correlations between spectral-domain OCT measurements and visual acuity in cystoid macular edema associated with retinitis pigmentosa. Investig Ophthalmol Vis Sci. 2013;54:1303–9.
doi: 10.1167/iovs.12-10149
Sousa K, Fernandes T, Gentil R, Mendonça L, Falcão M. Outer retinal layers as predictors of visual acuity in retinitis pigmentosa: a cross-sectional study. Graefe’s Arch Clin Exp Ophthalmol. 2019;257:265–71.
doi: 10.1007/s00417-018-4185-4
Oster SF, Mojana F, Brar M, Yuson RMS, Cheng L, Freeman WR. Disruption of the photoreceptor inner segment/outer segment layer on spectral domain-optical coherence tomography is a predictor of poor visual acuity in patients with epiretinal membranes. Retina. 2010;30:713–8.
doi: 10.1097/IAE.0b013e3181c596e3
Battaglia Parodi M, La Spina C, Triolo G, Riccieri F, Pierro L, Gagliardi M, et al. Correlation of SD-OCT findings and visual function in patients with retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2016;254:1275–9.
doi: 10.1007/s00417-015-3185-x
Cetin EN, Parca O, Akkaya HS, Pekel G. Association of retinal biomarkers and choroidal vascularity index on optical coherence tomography using binarization method in retinitis pigmentosa. Graefes Arch Clin Exp Ophthalmol. 2020;258:23–30.
doi: 10.1007/s00417-019-04516-7
Govetto A, Su D, Farajzadeh M, Megerdichian A, Platner E, Ducournau Y, et al. Microcystoid macular changes in association with idiopathic epiretinal membranes in eyes with and without glaucoma: clinical insights. Am J Ophthalmol. 2017;181:156–65.
doi: 10.1016/j.ajo.2017.06.023
Dolz-Marco R, Hoang QV, Gallego-Pinazo R, Chang S, ASSESSMENT OF. The significance of cystic changes after epiretinal membrane surgery with internal limiting membrane removal. Retina. 2016;36:727–32.
doi: 10.1097/IAE.0000000000000780
Burggraaff MC, Trieu J, de Vries-Knoppert WAEJ, Balk L, Petzold A. The clinical spectrum of microcystic macular edema. Investig Ophthalmol Vis Sci. 2014;55:952–61.
doi: 10.1167/iovs.13-12912
Abegg M, Dysli M, Wolf S, Kowal J, Dufour P, Zinkernagel M. Microcystic macular edema: Retrograde maculopathy caused by optic neuropathy. Ophthalmology. 2014;121:142–9.
doi: 10.1016/j.ophtha.2013.08.045
Querques G, Kamami-Levy C, Georges A, Pedinielli A, Capuano V, Blanco-Garavito R, et al. Adaptive optics imaging of foveal sparing in geographic atrophy secondary to age-related macular degeneration. Retina. 2016;36:247–54.
doi: 10.1097/IAE.0000000000000692
Fleckenstein M, Mitchell P, Freund KB, Sadda SV, Holz FG, Brittain C, et al. The progression of geographic atrophy secondary to age-related macular degeneration. Ophthalmology. 2018;125:369–90.